Applicable Bluebird In. License Section 1.1 Applicable New In-License Section 1.2 Applicable Pre-Existing In-License Section 1.3 Bankruptcy Code Section 3.7 Biosimilar Application Section 7.2(f) Biosilimar Product Section 1.4 Biosimilar Product Competition Section 4.3(e) Bluebird Preamble Bluebird In-Licensed IP Section 1.5 Bluebird Indemnitees Section 9.6(a) Bluebird Technology Section 1.6 Business Acquisition Section 3.4(b) Business Party Section 3.4(b) Business Program Section 3.4(b) Celgene Preamble Celgene Corp Preamble Celgene Development & Commercialization Program Section 1.7 Celgene Europe Preamble Celgene Indemnitees Section 9.6(b) Celgene Licensed Product In-License Section 1.8 Celgene Licensed Product In-Licensed IP Section 1.9 Celgene Licensed Product IP Section 1.10 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
Appears in 1 contract
Sources: Master Collaboration Agreement (Bluebird Bio, Inc.)
Applicable Bluebird In. License Section 1.1 Applicable New In-License Section 1.2 Applicable Pre-Existing In-License Section 1.3 Bankruptcy Code Section 3.7 Biosimilar Application Section 7.2(f) Biosilimar Product Section 1.4 Biosimilar Product Competition Section 4.3(e) Bluebird Preamble Bluebird In-Licensed IP Section 1.5 Bluebird Indemnitees Section 9.6(a) Bluebird Technology Section 1.6 Business Acquisition Section 3.4(b) Business Party Section 3.4(b) Business Program Section 3.4(b) Celgene Preamble Celgene Corp Preamble Celgene Development & Commercialization Program Section 1.7 Celgene Europe Preamble Celgene Indemnitees Section 9.6(b) Celgene Licensed Product In-License Section 1.8 Celgene Licensed Product In-Licensed IP Section 1.9 Celgene Licensed Product IP Section 1.10 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
Appears in 1 contract